PALTUSOTINE HYDROCHLORIDE - Generic Drug Details
What are the generic sources for paltusotine hydrochloride and what is the scope of patent protection?
Paltusotine hydrochloride
is the generic ingredient in one branded drug marketed by Crinetics and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.One supplier is listed for this compound.
Summary for PALTUSOTINE HYDROCHLORIDE
| International Patents: | 110 |
| US Patents: | 9 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 7 |
| Patent Applications: | 29 |
| DailyMed Link: | PALTUSOTINE HYDROCHLORIDE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PALTUSOTINE HYDROCHLORIDE
Generic Entry Date for PALTUSOTINE HYDROCHLORIDE*:
Constraining patent/regulatory exclusivity:
TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for PALTUSOTINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Crinetics Pharmaceuticals Inc. | PHASE3 |
| Crinetics Pharmaceuticals Inc. | Phase 3 |
| Crinetics Pharmaceuticals Inc. | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for PALTUSOTINE HYDROCHLORIDE
US Patents and Regulatory Information for PALTUSOTINE HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Crinetics | PALSONIFY | paltusotine hydrochloride | TABLET;ORAL | 219070-002 | Sep 25, 2025 | RX | Yes | Yes | 11,957,674 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Crinetics | PALSONIFY | paltusotine hydrochloride | TABLET;ORAL | 219070-001 | Sep 25, 2025 | RX | Yes | No | 9,896,432 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Crinetics | PALSONIFY | paltusotine hydrochloride | TABLET;ORAL | 219070-002 | Sep 25, 2025 | RX | Yes | Yes | 10,597,377 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Crinetics | PALSONIFY | paltusotine hydrochloride | TABLET;ORAL | 219070-001 | Sep 25, 2025 | RX | Yes | No | 11,414,397 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for PALTUSOTINE HYDROCHLORIDE
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2017296392 | ⤷ Start Trial | |
| Australia | 2020277122 | ⤷ Start Trial | |
| Brazil | 112019000692 | ⤷ Start Trial | |
| Canada | 3030423 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PALTUSOTINE HYDROCHLORIDE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3484865 | C20260018 | Finland | ⤷ Start Trial | |
| 3484865 | 301394 | Netherlands | ⤷ Start Trial | PRODUCT NAME: PALTUSOTINE IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VORM; REGISTRATION NO/DATE: EU/1/26/2021 20260427 |
| 3484865 | 2026C/739 | Belgium | ⤷ Start Trial | PRODUCT NAME: LA PALTUSOTINE SOUS TOUTES SES FORMES PROTEGEE PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/26/2021 20260423 |
| 3484865 | LUC50062 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: PALTUSOTINE SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/26/2021 20260427 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
